J. A. Marin-acevedo, B. Dholaria, A. E. Soyano, K. L. Knutson, C. S. Lou et al., Next generation of immune checkpoint therapy in cancer: New developments and challenges, J Hematol Oncol, vol.11, p.39, 2018.

T. L. Whiteside, S. Demaria, M. E. Rodriguez-ruiz, H. M. Zarour, and I. Melero, Emerging opportunities and challenges in cancer immunotherapy, Clin Cancer Res, vol.22, pp.1845-1855, 2016.

P. Schmid, S. Adams, H. S. Rugo, A. Schneeweiss, C. H. Barrios et al., Emens LA and IMpassion130 Trial Investigators: Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer, N Engl J Med, vol.379, pp.2108-2121, 2018.

A. Rodallec, G. Sicard, R. Fanciullino, S. Benzekry, B. Lacarelle et al., Turning cold tumors into hot tumors: Harnessing the potential of tumor immunity using nanoparticles, Expert Opin Drug Metab Toxicol, vol.11, pp.1139-11475, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01958583

G. V. Long, R. Dummer, O. Hamid, T. Gajewski, C. Caglevic et al., Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study, J Clin Oncol, vol.36, pp.108-108, 2018.

A. Grothey, J. Tabernero, D. Arnold, D. Gramont, A. Ducreux et al., Fluoropyrimidine and bevacizumab plus or minus atezolizumab as first-line treatment for BRAF wild-type metastatic colorectal cancer: Findings from the MODUL trial of biomarker-driven maintenance, p.19, 2018.

S. M. Mcbride, E. J. Sherman, C. J. Tsai, S. S. Baxi, J. Aghalar et al., A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC), J Clin Oncol, vol.15, pp.6009-6009, 2018.

O. Kepp, L. Galluzzi, I. Martins, F. Schlemmer, S. Adjemian et al., Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy, Cancer Metastasis Rev, vol.30, pp.61-69, 2011.

D. A. Schaer, R. P. Beckmann, J. A. Dempsey, L. Huber, A. Forest et al., The CDK4/6 inhibitor abemaciclib induces a T-cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade, Cell Rep, vol.22, pp.2978-2994, 2018.

D. Barbolosi, J. Ciccolini, B. Lacarelle, F. Barlési, and N. André, Computational oncology--mathematical modelling of drug regimens for precision medicine, Nat Rev Clin Oncol, vol.13, pp.242-254, 2016.

D. Barbolosi, J. Ciccolini, C. Meille, X. Elharrar, C. Faivre et al., Metronomics chemotherapy: time for computational decision support, Cancer Chemother Pharmacol, vol.74, pp.647-652, 2014.

S. Benzekry, E. Pasquier, D. Barbolosi, B. Lacarelle, F. Barlési et al., Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine, Semin Cancer Biol, vol.35, pp.53-61, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01195547

J. Ciccolini, D. Barbolosi, C. Meille, A. Lombard, C. Serdjebi et al., Pharmacokinetics and pharmacodynamics-based mathematical modeling identifies an optimal protocol for metronomic chemotherapy, Cancer Res, vol.77, pp.4723-4733, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01789578

F. Barlesi, D. Imbs, P. Tomasini, L. Greillier, M. Galloux et al., Mathematical modeling for phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients, Oncotarget, vol.8, pp.47161-47166, 2017.

M. Toulmonde, N. Penel, J. Adam, C. Chevreau, J. Blay et al., Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: A phase 2 clinical trial, JAMA Oncol, vol.4, pp.93-97, 2018.

M. Centanni, D. Moes, I. F. Trocóniz, C. J. Van-hasselt, and J. , Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors, Clin Pharmacokinet, 2019.

V. F. Cosson, V. W. Ng, M. Lehle, and B. L. Lum, Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer, Cancer Chemother Pharmacol, vol.73, pp.737-747, 2014.

F. Becher, J. Ciccolini, D. Imbs, C. Marin, C. Fournel et al., A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients, Sci Rep, vol.7, p.2714, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01606760

M. Tout, O. Casasnovas, M. Meignan, T. Lamy, F. Morschhauser et al., Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: A Lymphoma Study Association report, Blood, vol.129, pp.2616-2623, 2017.

M. Caulet, T. Lecomte, O. Bouché, J. Rollin, V. Gouilleux-gruart et al., Bevacizumab pharmacokinetics influence overall and progression-free survival in metastatic colorectal cancer patients, Clin Pharmacokinet, vol.55, pp.1381-1394, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01769811

C. R. Heery, G. O'sullivan-coyne, R. A. Madan, L. Cordes, A. Rajan et al., Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): A phase 1a, multicohort, dose-escalation trial, Lancet Oncol, vol.18, pp.587-598, 2017.

S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, vol.366, pp.2443-2454, 2012.

E. A. Basak, S. Koolen, D. P. Hurkmans, M. Schreurs, S. Bins et al., Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer, Eur J Cancer, vol.109, pp.12-20, 2019.

R. J. Keizer, A. Huitema, J. Schellens, and J. H. Beijnen, Clinical pharmacokinetics of therapeutic monoclonal antibodies, Clin Pharmacokinet, vol.49, pp.493-507, 2010.